Elisabetta Patorno, Dr.P.H., M.D.
Co-Author
This page shows the publications co-authored by Elisabetta Patorno and Robert Glynn.
Connection Strength
2.916
-
Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease. Ann Intern Med. 2021 Sep 28.
Score: 0.247
-
Trends in First-Line Glucose-Lowering Drug Use in Adults With Type 2 Diabetes in Light of Emerging Evidence for SGLT-2i and GLP-1RA. Diabetes Care. 2021 08; 44(8):1774-1782.
Score: 0.242
-
Comparative Effectiveness and Safety of Sodium-Glucose Cotransporter 2 Inhibitors Versus Glucagon-Like Peptide 1 Receptor Agonists in Older Adults. Diabetes Care. 2021 03; 44(3):826-835.
Score: 0.235
-
Risk of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-1RA Therapy. Circulation. 2021 Feb 23; 143(8):770-779.
Score: 0.233
-
Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study. BMJ. 2020 08 25; 370:m2812.
Score: 0.229
-
Measuring Frailty in Administrative Claims Data: Comparative Performance of Four Claims-Based Frailty Measures in the U.S. Medicare Data. J Gerontol A Biol Sci Med Sci. 2020 05 22; 75(6):1120-1125.
Score: 0.225
-
A tool for empirical equipoise assessment in multigroup comparative effectiveness research. Pharmacoepidemiol Drug Saf. 2019 07; 28(7):934-941.
Score: 0.210
-
Multinomial Extension of Propensity Score Trimming Methods: A Simulation Study. Am J Epidemiol. 2019 03 01; 188(3):609-616.
Score: 0.206
-
Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study. BMJ. 2018 02 06; 360:k119.
Score: 0.192
-
Benzodiazepines and risk of all cause mortality in adults: cohort study. BMJ. 2017 Jul 06; 358:j2941.
Score: 0.184
-
Comparative cardiovascular safety of glucagon-like peptide-1 receptor agonists versus other antidiabetic drugs in routine care: a cohort study. Diabetes Obes Metab. 2016 08; 18(8):755-65.
Score: 0.170
-
Studies with many covariates and few outcomes: selecting covariates and implementing propensity-score-based confounding adjustments. Epidemiology. 2014 Mar; 25(2):268-78.
Score: 0.146
-
Risk of ischemic cerebrovascular and coronary events in adult users of anticonvulsant medications in routine care settings. J Am Heart Assoc. 2013 Jul 30; 2(4):e000208.
Score: 0.140
-
Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies: First Results From the RCT DUPLICATE Initiative. Circulation. 2021 03 09; 143(10):1002-1013.
Score: 0.058
-
Risk Factors for Heart Failure with Preserved or Reduced Ejection Fraction Among Medicare Beneficiaries: Application of Competing Risks Analysis and Gradient Boosted Model. Clin Epidemiol. 2020; 12:607-616.
Score: 0.056
-
Continuation of Atypical Antipsychotic Medication During Early Pregnancy and the Risk of Gestational Diabetes. Am J Psychiatry. 2018 06 01; 175(6):564-574.
Score: 0.049
-
Use of haloperidol versus atypical antipsychotics and risk of in-hospital death in patients with acute myocardial infarction: cohort study. BMJ. 2018 03 28; 360:k1218.
Score: 0.048
-
Variable Selection for Confounding Adjustment in High-dimensional Covariate Spaces When Analyzing Healthcare Databases. Epidemiology. 2017 03; 28(2):237-248.
Score: 0.045
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.